A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
This study, called RISE UP, is testing a new medicine called mitapivat for people with sickle cell disease. It has two main goals: first, to find the best dose of mitapivat, and second, to see how well it works and if it's safe. Specifically, researchers want to know if mitapivat can help increase the amount of a healthy red blood cell chemical (hemoglobin) in the blood and reduce painful episodes called sickle cell crises. Over time, the study will also look at the longer-term effects of this medicine. If you have sickle cell disease, this study could be an opportunity to explore a potential new treatment.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
Sickle cell disease is a lifelong condition that affects your red blood cells. Normally, these cells are round and flexible, carrying oxygen around your body. But with sickle cell disease, they can become stiff and C-shaped, like a farm tool called a sickle. These 'sickled' cells can block blood flow, leading to severe pain, called sickle cell crises, and other health problems.
This study is investigating a new medicine called mitapivat. It's designed to help your blood cells work better. The researchers want to find out the best amount of mitapivat to give and how well it helps people with sickle cell disease. They will be looking to see if it can increase healthy red blood cells and reduce the number of painful crises you might experience. It's important to remember that this is a research study, and we're still learning about this medicine.
The study is split into two main parts, called Phase 2 and Phase 3. The first part helps find the right dose. Then, a larger group of people will take part in Phase 3 to get a clearer picture of how effective and safe mitapivat is compared to a dummy pill (placebo). After these main parts, there's an option to continue taking mitapivat for a longer period to see its long-term effects.
النقاط الرئيسية
- This study is testing a new medicine called mitapivat for sickle cell disease.
- It aims to find the right dose and see if it helps increase red blood cells and reduce painful crises.
- The study involves taking either mitapivat or a dummy pill (placebo).
- Participation includes regular clinic visits and health checks.
- Potential benefits might include access to a new treatment, but there are also potential side effects.
- يمكنك مغادرة الدراسة في أي وقت دون التأثير على رعايتك العادية.
من قد يكون مؤهلاً؟
To join this study, you need to be at least 16 years old. (In France and Germany, you must be 18 or older). If you're 16 or 17, you must have finished puberty. You need to have a clear diagnosis of sickle cell disease, including common types like HbSS or HbSC.
Over the past year, you should have experienced at least two, but no more than ten, painful sickle cell crises. Your haemoglobin level (a measure of your red blood cells) needs to be within a specific range. If you're currently taking a medicine called hydroxyurea, your dose must have been stable for at least 3 months. Women who could become pregnant must agree to use two types of birth control during the study.
There are also some reasons you wouldn't be able to join. For example, if you are pregnant or breastfeeding, or if you regularly receive blood transfusions. You would also be excluded if you have certain severe liver or kidney problems, or if you've had a stem cell transplant or gene therapy. Also, if you're taking certain other ongoing sickle cell medicines or investigational treatments, you might not be eligible.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Are you 16 years or older? (18+ in France/Germany)
- Do you have a diagnosis of sickle cell disease?
- Have you had 2 to 10 painful sickle cell crises in the last year?
- Are you able to use two forms of contraception if you could become pregnant?
- هل أنتِ لستِ حاملاً أو مرضعة؟
- Are you NOT regularly having blood transfusions?
ماذا يتضمن المشاركة؟
If you decide to take part, the study will involve several visits to a clinic. You'll be given either mitapivat or a dummy pill (placebo) to take. Initially, the study will involve different doses of mitapivat being tested in smaller groups. Then, in the main part, you'll either take the recommended dose of mitapivat or a placebo for about 52 weeks (roughly a year). This will be decided by chance, like flipping a coin. You won't know if you're getting the active medicine or the placebo, and neither will your local study doctor.
Throughout the study, you'll have regular checks, which might include blood tests, physical exams, and discussions about how you're feeling and any symptoms you have. The study team will explain all the procedures in detail. After the main part of the study, you might have the option to continue taking mitapivat for up to 216 weeks (over 4 years) in an open-label part, meaning everyone in this part would receive mitapivat.
المخاطر والفوائد المحتملة
المواقع (91)
- جامعة كاليفورنيا سان دييغوالرمز البريدي المؤكدلا جولا، الولايات المتحدة
- UCLA Healthالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة
- Children's Hospital Oaklandالرمز البريدي المؤكدأوكلاند، الولايات المتحدة
- University of Connecticut Health Centerالرمز البريدي المؤكدفارمينغتون، الولايات المتحدة
- مستشفى الأطفال الوطنيالرمز البريدي المؤكدواشنطن العاصمة، الولايات المتحدة
- MedStar Washington Hospital Centerالرمز البريدي المؤكدواشنطن العاصمة، الولايات المتحدة
- Sylvester Comprehensive Cancer Center-Miamiالرمز البريدي المؤكدميامي، الولايات المتحدة
- مركز جامعة شيكاغو الطبيالرمز البريدي المؤكدشيكاغو، الولايات المتحدة
- Riley Hospital For Childrenالرمز البريدي المؤكدإنديانابوليس، الولايات المتحدة
- LSU Health Sciences Center - Shreveportالرمز البريدي المؤكدشريفبورت، الولايات المتحدة
- National Heart Lung and Blood Instituteالرمز البريدي المؤكدبيثيسدا، الولايات المتحدة
- Kaiser Permanente - Largo Medical Centerالرمز البريدي المؤكدLargo, United States
أسئلة شائعة
What is sickle cell disease?
It's a blood condition where red blood cells become stiff and C-shaped, causing pain and other health issues.
What is mitapivat?
It's a new medicine being tested to help make red blood cells healthier and reduce pain crises in people with sickle cell disease.
ما هو الدواء الوهمي؟
A placebo is a dummy pill that looks like the real medicine but contains no active ingredients. It helps researchers see if the real medicine is truly effective.
How long would I need to be in the study?
The main part of the study lasts about a year, with an option to continue for several more years afterwards.
Can I still take my regular medicines?
You might be able to, but some medicines need to be stopped or stable for a certain time before joining. The study team will tell you which ones.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.